SBC Medical Group Holdings Incorporated Financing Receivable, Change in Method, Credit Loss Expense (Reversal)
SBC Medical Group Holdings Incorporated (SBC) reported Financing Receivable, Change in Method, Credit Loss Expense (Reversal) of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinancingReceivableChangeInMethodCreditLossExpenseReversal · last filed 2026-08-13
- SBC Medical Group Holdings Incorporated financing receivable, change in method, credit loss expense (reversal) for the quarter ending 2026-06-30 was $0.00.
- SBC Medical Group Holdings Incorporated financing receivable, change in method, credit loss expense (reversal) for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- SBC Medical Group Holdings Incorporated financing receivable, change in method, credit loss expense (reversal) for the quarter ending 2025-12-31 was $3.01K, a 98.92% decline year-over-year.
- SBC Medical Group Holdings Incorporated financing receivable, change in method, credit loss expense (reversal) for the quarter ending 2025-09-30 was $0.00.
- SBC Medical Group Holdings Incorporated financing receivable, change in method, credit loss expense (reversal) for fiscal 2025 was $73.01K, a 92.88% decline from fiscal 2024.
- SBC Medical Group Holdings Incorporated financing receivable, change in method, credit loss expense (reversal) for fiscal 2024 was $1.02M.
| Period end | Financing Receivable, Change in Method, Credit Loss Expense (Reversal) 3 month | Financing Receivable, Change in Method, Credit Loss Expense (Reversal) 6 month | Financing Receivable, Change in Method, Credit Loss Expense (Reversal) 6 month as first filed | Financing Receivable, Change in Method, Credit Loss Expense (Reversal) 9 month | Financing Receivable, Change in Method, Credit Loss Expense (Reversal) 9 month as first filed | Financing Receivable, Change in Method, Credit Loss Expense (Reversal) 12 month | Financing Receivable, Change in Method, Credit Loss Expense (Reversal) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $3.01K derived: sum of 3 quarters · filed 2026-08-13 | $3.01K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | $3.01K derived: sum of 2 quarters · filed 2026-05-14 | $3.01K derived: sum of 3 quarters · filed 2026-05-14 | $3.01K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $3.01K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $3.01K derived: sum of 2 quarters · filed 2026-03-27 | $3.01K derived: sum of 3 quarters · filed 2026-08-13 | $73.01K 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $70.00K 10-Q · filed 2025-11-14 | $350.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $70.00K 10-Q · filed 2026-08-13 | -$70.00K 10-Q · filed 2025-08-13 | $350.00K derived: sum of 3 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $70.00K 10-Q · filed 2026-05-14 | $350.00K derived: sum of 2 quarters · filed 2026-05-14 | |||||
| 2024-12-31 | $280.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.02M 10-K · filed 2026-03-27 | -$1.02M 10-K · filed 2025-03-28 | ||||
| 2024-09-30 | $745.00K 10-Q · filed 2025-11-14 | -$745.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Airsculpt Technologies, Inc. (AIRS) | United States | $0.146B | -27.36 |
| LifeMD, Inc. (LFMD) | United States | $0.141B | 982.53 |
| Teladoc Health, Inc. (TDOC) | United States | $1.114B | -8.68 |